CLINICAL TRIALS PROFILE FOR MDP-BRACCO

All Clinical Trials for Mdp-bracco

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00590070 ↗	THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction	Completed	Catholic University of the Sacred Heart	Phase 2/Phase 3	2008-01-01	The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases. This event is associated with a worse prognosis at follow up and an unfavourable left ventricular remodelling . Two main pathogenetic mechanisms cause no-reflow: distal embolization and ischemia-reperfusion injury. Due to the multifactorial pathogenesis of no-reflow during acute MI a combined mechanic and pharmacologic approach is believed to offer a better solution for achieving optimal microvascular reperfusion. Thus, in this randomized study we will assess the effect of nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and IIb-IIIa antagonists) for ST elevation MI using ST segment resolution on standard 12 leads ECG as primary endpoint of myocardial reperfusion.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Johns Hopkins University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Memorial Health University Medical Center	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Penn State University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Temple University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT01481441 ↗	Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer	Terminated	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A	2011-11-01	With Contrast Enhanced UltraSound (CEUS) cancer induced neovascularisation can be visualised with the potential to improve ultrasound imaging for prostate cancer detection and localisation significantly. The past years numerous studies have been performed with CEUS, all basing their results on subjective judgement of the investigator. CEUS image interpretation is difficult and requires a well-trained expert. To overcome these difficulties CEUS quantification techniques can be of use. The techniques used in this protocol have been developed in cooperation with the Technical University in Eindhoven (TU/e) and BRACCO, Geneva. The investigators hypothesize improvement of the PCa detection rate with quantification, compared with subjective CEUS interpretation and known numbers in literature. Also a comparison between quantification results and tumour differentiation grade (Gleason score) will be made, the investigators hypothesize a positive correlation.
NCT02502747 ↗	RIGENERA 2.0 Trial	Suspended	Catholic University of the Sacred Heart	Phase 2	2020-01-01	Study Objectives: To determine whether, in patients with large acute myocardial infarction undergoing primary or rescue angioplasty, the administration of subcutaneous Lenograstim [recombinant human Granulocyte-Colony Stimulating Factor (rhu G-CSF), Myelostim 34, Italfarmaco] associated with Myocardial Contrast Echocardiography and the intravenous infusion of sulphur hexafluoride (Sonovue, Bracco) determines an improvement: - in regional and global contractile function, myocardial perfusion and infarct size assessed by cardiovascular magnetic resonance. - Echocardiographic parameters of LV function - in the serum profile of inflammatory and mobilizing cytokines and of biomarkers of myocardial damage and wall stress

Clinical Trial Conditions for Mdp-bracco

Condition Name

Condition Name for Mdp-bracco
Intervention	Trials
Early Primary Breast Cancer	1
Post Operative Pain	1
Healthy	1
Prostate Cancer	1

Condition MeSH

Condition MeSH for Mdp-bracco
Intervention	Trials
Myocardial Infarction	3
Infarction	3
Breast Neoplasms	1
Hypoxia-Ischemia, Brain	1

Clinical Trial Locations for Mdp-bracco

Trials by Country

Trials by Country for Mdp-bracco
Location	Trials
United States	10
Italy	2
Germany	1
Netherlands	1
Belgium	1

Trials by US State

Trials by US State for Mdp-bracco
Location	Trials
Pennsylvania	4
North Carolina	1
Massachusetts	1
Illinois	1
Arizona	1

Clinical Trial Progress for Mdp-bracco

Clinical Trial Phase

Clinical Trial Phase for Mdp-bracco
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Mdp-bracco
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Terminated	2

Clinical Trial Sponsors for Mdp-bracco

Sponsor Name

Sponsor Name for Mdp-bracco
Sponsor	Trials
Children's Hospital of Philadelphia	3
Bracco Diagnostics, Inc	2
Catholic University of the Sacred Heart	2

Sponsor Type

Sponsor Type for Mdp-bracco
Sponsor	Trials
Other	22
Industry	4

Clinical Trials, Market Analysis, and Projections for Bracco's Diagnostic and Therapeutic Products

Introduction to Bracco

Bracco, an Italian multinational company, is a significant player in the healthcare sector, particularly in diagnostic imaging, contrast agents, and advanced medical devices. With a global presence in over 100 countries and a workforce of more than 3,300 employees, Bracco is at the forefront of innovative healthcare solutions[2].

Clinical Trials Update

Diagnostic Imaging: POSLUMA (Flotufolastat F 18)

One of the notable clinical trials involving Bracco's products is the Phase 3 SPOTLIGHT study for POSLUMA (flotufolastat F 18), a PET/CT radiopharmaceutical. This study, conducted by Blue Earth Diagnostics, a Bracco company, evaluated the diagnostic performance of POSLUMA in patients with recurrent prostate cancer. The results validated the diagnostic performance of POSLUMA, particularly in African American men, and highlighted its broad applicability across the U.S. population[4].

Therapeutic Trials: Avutometinib and Defactinib

Although not directly related to Bracco, it's worth noting the advancements in therapeutic trials that could impact the broader healthcare landscape. For instance, Verastem Oncology's RAMP 205 trial, which evaluates the combination of avutometinib and defactinib with standard chemotherapy in first-line metastatic pancreatic cancer, has shown promising initial interim results. This trial underscores the importance of targeting the RAS/MAPK pathway, a common mutation in pancreatic tumors[1].

Market Analysis

Contrast Media Market

The contrast media market, in which Bracco is a key player, is projected to grow significantly. The global contrast media market is estimated to be around USD 5.77 billion in 2024 and is expected to reach USD 6.59 billion by 2029, growing at a CAGR of 7.44% during the forecast period[5].

Contrast Media Injectors Market

The contrast media injectors market, another area where Bracco has a strong presence, is also anticipated to see substantial growth. This market is estimated at USD 1.82 billion in 2024 and is expected to reach USD 2.59 billion by 2029, with a CAGR of 7.44% during the forecast period[5].

Nuclear Imaging Market

In specific regions, the nuclear imaging market, which includes Bracco's diagnostic products, is also growing. For example:

• The Canada nuclear imaging market is expected to grow from USD 500.24 million in 2024 to USD 596.56 million by 2029, at a CAGR of 3.57%[5].
• The Mexico nuclear imaging market is projected to grow from USD 182.67 million in 2024 to USD 208.95 million by 2029, at a CAGR of 2.68%[5].
• The Argentina nuclear imaging market is expected to grow from USD 95.95 million in 2024 to USD 108.82 million by 2029, at a CAGR of 2.55%[5].

Projections and Future Outlook

Global Expansion and Innovation

Bracco's continued investment in research and innovation, with approximately 10% of its core diagnostic imaging revenues dedicated to this area, positions the company for sustained growth. The company's global expansion, including its presence in China since 2002 and recent acquisitions, further solidifies its market position[2].

Technological Advancements

The development of novel diagnostic tools like POSLUMA, which leverages high-affinity PSMA-targeted PET radiopharmaceuticals, indicates Bracco's commitment to technological advancements. These innovations are likely to drive market growth and improve diagnostic outcomes in various medical conditions[4].

Regulatory and Collaborative Efforts

Bracco's involvement in various clinical trials and collaborations, such as the SPOTLIGHT study, demonstrates its ability to navigate regulatory environments and collaborate with other industry leaders. This strategic approach is crucial for the successful launch and adoption of new diagnostic and therapeutic products[4].

Key Takeaways

• Clinical Trials: Bracco's products, such as POSLUMA, are undergoing rigorous clinical trials to validate their diagnostic performance.
• Market Growth: The contrast media and nuclear imaging markets are projected to grow significantly over the next few years.
• Innovation: Bracco's investment in research and development is driving technological advancements in diagnostic imaging.
• Global Presence: The company's expanding global footprint and strategic acquisitions are key factors in its market success.

FAQs

1. What is POSLUMA, and what is its significance in diagnostic imaging?

   • POSLUMA (flotufolastat F 18) is a PET/CT radiopharmaceutical used for diagnosing recurrent prostate cancer. It represents a newer class of high-affinity PSMA-targeted PET radiopharmaceuticals and has shown broad applicability across different patient populations[4].

2. How is Bracco positioned in the global contrast media market?

   • Bracco is a significant player in the global contrast media market, which is expected to grow from USD 5.77 billion in 2024 to USD 6.59 billion by 2029[5].

3. What are the key regions for Bracco's nuclear imaging market growth?

   • Key regions include Canada, Mexico, and Argentina, where the nuclear imaging markets are expected to grow at various CAGRs over the next few years[5].

4. How does Bracco's investment in research and development impact its market position?

   • Bracco's investment in research and development, approximately 10% of its core diagnostic imaging revenues, drives technological advancements and positions the company for sustained growth and innovation[2].

5. What are some of the recent acquisitions and collaborations that have enhanced Bracco's market presence?

   • Recent acquisitions include Bracco Eisai joint venture in Japan, Squibb Diagnostic in the US, and E-Z-EM. Collaborations such as the SPOTLIGHT study further enhance Bracco's market presence and innovation capabilities[2].

Sources

1. Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial - Investor Verastem Oncology.
2. Bracco (company) - Wikipedia.
3. Modern Challenges in Type 2 Diabetes: Balancing New Medications - MDPI.
4. Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA - ITN Online.
5. Bracco Reports - Industry Research - Mordor Intelligence.